Evidence map›Paper›PMID 27162537›Full record

ArticleJournal of Cancer2016

Survival and Quality of Life Benefit after Endoscopic Management of Malignant Central Airway Obstruction.

Grigoris Stratakos, Vasiliki Gerovasili, Charalampos Dimitropoulos, Ioannis Giozos, Filippos T Filippidis, Sofia Gennimata, Paul Zarogoulidis, Athanasios Zissimopoulos, Athanasia Pataka, Nikos Koufos and 3 more

Abstract read
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Interventional bronchoscopy in lung cancer treatment.Breathe (Sheffield, England) · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Grigoris Stratakos1. 1st Pulmonary Medicine Department of National and Kapodistrian University of Athens, "Sotiria" General Hospital Athens, Greece;
Vasiliki Gerovasili2. 1st Respiratory and Critical Care Medicine department of National and Kapodistrian University of Athens, "Evangelismos" Hospital Athens, Greece;
Charalampos Dimitropoulos1. 1st Pulmonary Medicine Department of National and Kapodistrian University of Athens, "Sotiria" General Hospital Athens, Greece;
Ioannis Giozos3. Oncology Unit, 3rd Department of Internal Medicine of National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, Greece;
Filippos T Filippidis2. 1st Respiratory and Critical Care Medicine department of National and Kapodistrian University of Athens, "Evangelismos" Hospital Athens, Greece;
Sofia Gennimata1. 1st Pulmonary Medicine Department of National and Kapodistrian University of Athens, "Sotiria" General Hospital Athens, Greece;
Paul Zarogoulidis4. Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
Athanasios Zissimopoulos5. Nuclear Medicine Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Athanasia Pataka4. Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
Nikos Koufos1. 1st Pulmonary Medicine Department of National and Kapodistrian University of Athens, "Sotiria" General Hospital Athens, Greece;
Spyros Zakynthinos2. 1st Respiratory and Critical Care Medicine department of National and Kapodistrian University of Athens, "Evangelismos" Hospital Athens, Greece;
Konstantinos Syrigos3. Oncology Unit, 3rd Department of Internal Medicine of National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, Greece;
Nikos Koulouris1. 1st Pulmonary Medicine Department of National and Kapodistrian University of Athens, "Sotiria" General Hospital Athens, Greece;

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough interventional management of malignant central airway obstruction (mCAO) is well established, its impact on survival and quality of life (QoL) has not been extensively studied.

aimWe prospectively assessed survival, QoL and dyspnea (using validated EORTC questionnaire) in patients with mCAO 1 day before interventional bronchoscopy, 1 week after and every following month, in comparison to patients who declined this approach. Material/Patients/Methods: 36 patients underwent extensive interventional bronchoscopic management as indicated, whereas 12 declined. All patients received full chemotherapy and radiotherapy as indicated. Patients of the 2 groups were matched for age, comorbidities, type of malignancy and level of obstruction. Follow up time was 8.0±8.7 (range 1-38) months.

resultsMean survival for intervention and control group was 10±9 and 4±3 months respectively (p=0.04). QoL improved significantly in intervention group patients up to the 6(th) month (p<0.05) not deteriorating for those surviving up to 12 months. Dyspnea decreased in patients of the intervention group 1 month post procedure remaining reduced for survivors over the 12th month. Patients of the control group had worse QoL and dyspnea in all time points.

conclusionsInterventional management of patients with mCAO, may achieve prolonged survival with sustained significant improvement of QoL and dyspnea.

Indexed as

interventionlung cancerquality of life.

Identifiers

PMID27162537
PMCPMC4860795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.